- Home
- NCPL vs NCNA Comparison
NCPL vs NCNA Comparison
Compare NCPL & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- NCNA
- Stock Information
- Founded
- NCPL 1984
- NCNA 1997
- Country
- NCPL United States
- NCNA United Kingdom
- Employees
- NCPL N/A
- NCNA N/A
- Industry
- NCPL Investment Managers
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- NCNA Health Care
- Exchange
- NCPL Nasdaq
- NCNA Nasdaq
- Market Cap
- NCPL 16.1M
- NCNA 15.4M
- IPO Year
- NCPL N/A
- NCNA 2017
- Fundamental
- Price
- NCPL $2.49
- NCNA $4.47
- Analyst Decision
- NCPL
- NCNA Buy
- Analyst Count
- NCPL 0
- NCNA 2
- Target Price
- NCPL N/A
- NCNA $25.00
- AVG Volume (30 Days)
- NCPL 366.8K
- NCNA 187.0M
- Earning Date
- NCPL 09-15-2025
- NCNA 08-18-2025
- Dividend Yield
- NCPL N/A
- NCNA N/A
- EPS Growth
- NCPL N/A
- NCNA N/A
- EPS
- NCPL N/A
- NCNA N/A
- Revenue
- NCPL $812,612.00
- NCNA N/A
- Revenue This Year
- NCPL N/A
- NCNA N/A
- Revenue Next Year
- NCPL $101.16
- NCNA N/A
- P/E Ratio
- NCPL N/A
- NCNA N/A
- Revenue Growth
- NCPL N/A
- NCNA N/A
- 52 Week Low
- NCPL $1.41
- NCNA $0.03
- 52 Week High
- NCPL $8.75
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- NCPL 36.18
- NCNA 30.91
- Support Level
- NCPL $2.81
- NCNA $7.06
- Resistance Level
- NCPL $3.45
- NCNA $10.00
- Average True Range (ATR)
- NCPL 0.33
- NCNA 1.44
- MACD
- NCPL -0.07
- NCNA 0.07
- Stochastic Oscillator
- NCPL 16.79
- NCNA 3.94
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.